{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:14:16Z","timestamp":1783509256220,"version":"3.55.0"},"reference-count":34,"publisher":"MDPI AG","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5]]},"abstract":"Antiphospholipid syndrome is an autoimmune disease characterized by vascular thrombosis involving both the arterial and venous systems that can lead to tissue ischemia or end-organ damage. Much of the literature describes various symptoms at initial presentation, but isolated tissue ischemia manifesting as a solitary blue toe is unusual. We discuss a case of a 23-year-old man who presented to the emergency department with a solitary blue fourth digit with minimal erythema and edema, who was suffering from exquisite pain. Following an extensive workup, the patient was diagnosed with antiphospholipid syndrome with thrombi of the vasculature in their lower extremity. With therapeutic anticoagulation, the patient's symptoms subsided and amputation of the digit was prevented.<\/jats:p>","DOI":"10.7547\/17-108","type":"journal-article","created":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T12:09:53Z","timestamp":1562155793000},"page":"235-240","source":"Crossref","is-referenced-by-count":6,"title":["The Solitary Blue Toe: A Unique Presentation of Antiphospholipid Syndrome"],"prefix":"10.3390","volume":"109","author":[{"given":"Devin G.","family":"Dimond","sequence":"first","affiliation":[{"name":"St. Mary's Medical Center, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny K.","family":"Lam","sequence":"additional","affiliation":[{"name":"St. Mary's Medical Center, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Wurster","sequence":"additional","affiliation":[{"name":"St. Mary's Medical Center, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Kiser","sequence":"additional","affiliation":[{"name":"Samuel Merritt University, Oakland, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Driscoll","sequence":"additional","affiliation":[{"name":"Samuel Merritt University, Oakland, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Razzante","sequence":"additional","affiliation":[{"name":"Saint Vincent Charity Medical Center, Cleveland, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","reference":[{"key":"i8750-7315-109-3-235-b01","series-title":"Lupus","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1177\/0961203314537362","article-title":"The autoimmune tautology with a focus on antiphospholipid syndrome","volume":"23","author":"Franco \n J,","year":"2014","unstructured":"Franco \n J, \n \n \n Anaya \n J: \n \n \n The autoimmune tautology with a focus on antiphospholipid syndrome. Lupus23: 1273, 2014.10.1177\/096120331453736225228724"},{"key":"i8750-7315-109-3-235-b02","series-title":"Int J Rheum Disease","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/1756-185X.12438","article-title":"Antiphospholipid syndrome: 30 years and our contribution","volume":"18","author":"Koike \n T:","year":"2015","unstructured":"Koike \n T: \n \n \n Antiphospholipid syndrome: 30 years and our contribution. Int J Rheum Disease18: 233, 2015.10.1111\/1756-185X.12438"},{"key":"i8750-7315-109-3-235-b03","series-title":"J Thromb Haemost","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome","volume":"4","author":"Miyakis \n M,","year":"2006","unstructured":"Miyakis \n M, \n \n \n Lockshin \n T, \n \n \n Atsumi \n D, \n \n et al: \n International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost4: 295, 2006.10.1111\/j.1538-7836.2006.01753.x"},{"key":"i8750-7315-109-3-235-b04","series-title":"Curr Opin Rheumatol","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/BOR.0000000000000240","article-title":"Recognition and management of antiphospholipid syndrome","volume":"28","author":"Gerosa \n M,","year":"2016","unstructured":"Gerosa \n M, \n \n \n Meroni \n PL, \n \n \n Erkan \n D: \n \n \n Recognition and management of antiphospholipid syndrome. Curr Opin Rheumatol28: 51, 2016.2659938210.1097\/BOR.0000000000000240"},{"key":"i8750-7315-109-3-235-b05","series-title":"J Autoimmun","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jaut.2014.01.006","article-title":"Diagnosis and classification of the antiphospholipid syndrome","volume":"48","author":"Gomez-Puerta \n JA,","year":"2014","unstructured":"Gomez-Puerta \n JA, \n \n \n Cervera \n R: \n \n \n Diagnosis and classification of the antiphospholipid syndrome. J Autoimmun48: 20, 2014.2446153910.1016\/j.jaut.2014.01.006"},{"key":"i8750-7315-109-3-235-b06","series-title":"J Vasc Surg","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jvs.2008.02.052","article-title":"Superficial femoral artery thrombosis as a cause for distal embolism in primary antiphospholipid syndrome","volume":"48","author":"Lauvao \n LS,","year":"2008","unstructured":"Lauvao \n LS, \n \n \n Goshima \n KR, \n \n \n Leon \n LR, \n \n et al: \n Superficial femoral artery thrombosis as a cause for distal embolism in primary antiphospholipid syndrome. J Vasc Surg48: 47, 2008.10.1016\/j.jvs.2008.02.052"},{"key":"i8750-7315-109-3-235-b07","series-title":"Lupus","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1177\/0961203314540015","article-title":"Cardiovascular disease in the antiphospholipid syndrome","volume":"23","author":"Amaya-Amaya \n J,","year":"2014","unstructured":"Amaya-Amaya \n J, \n \n \n Rojas-Villarraga \n A, \n \n \n Anaya \n JM: \n \n \n Cardiovascular disease in the antiphospholipid syndrome. Lupus23: 1288, 2014.2522872910.1177\/0961203314540015"},{"key":"i8750-7315-109-3-235-b08","series-title":"Am J Med","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.amjmed.2015.01.010","article-title":"Reconcilable differences: idiopathic antiphospholipid syndrome","volume":"128","author":"Chen \n YG,","year":"2015","unstructured":"Chen \n YG, \n \n \n Peng \n CK, \n \n \n Dai \n MS, \n \n et al: \n Reconcilable differences: idiopathic antiphospholipid syndrome. Am J Med128: 471, 2015.2565611110.1016\/j.amjmed.2015.01.010"},{"key":"i8750-7315-109-3-235-b09","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1056\/NEJMra1112830","article-title":"The pathogenesis of the antiphospholipid syndrome","volume":"368","author":"Giannakopoulos \n B,","year":"2013","unstructured":"Giannakopoulos \n B, \n \n \n Krilis \n SA: \n \n \n The pathogenesis of the antiphospholipid syndrome. N Engl J Med368: 1033, 2013.2348483010.1056\/NEJMra1112830"},{"key":"i8750-7315-109-3-235-b10","series-title":"Semin Thromb Hemost","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1055\/s-0035-1556725","article-title":"Antiphospholipid syndrome: not a noninflammatory disease","volume":"41","author":"de Groot \n PG,","year":"2015","unstructured":"de Groot \n PG, \n \n \n Urbanus \n RT: \n \n \n Antiphospholipid syndrome: not a noninflammatory disease. Semin Thromb Hemost41: 607, 2015.2627693510.1055\/s-0035-1556725"},{"key":"i8750-7315-109-3-235-b11","series-title":"Rheum Dis Clin North Am","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.rdc.2014.09.009","article-title":"Vasculitis in antiphospholipid syndrome","volume":"41","author":"Lally \n L,","year":"2015","unstructured":"Lally \n L, \n \n \n Sammaritano \n L: \n \n \n Vasculitis in antiphospholipid syndrome. Rheum Dis Clin North Am41: 109, 2015.10.1016\/j.rdc.2014.09.00925399943"},{"key":"i8750-7315-109-3-235-b12","series-title":"Ann Intern Med","doi-asserted-by":"publisher","first-page":"893","DOI":"10.7326\/0003-4819-113-11-893","article-title":"Corticosteroid-associated blue toe syndrome: role of antiphospholipid antibodies","volume":"113","author":"Davies \n GE,","year":"1990","unstructured":"Davies \n GE, \n \n \n Triplett \n DA: \n \n \n Corticosteroid-associated blue toe syndrome: role of antiphospholipid antibodies. Ann Intern Med113: 893, 1990.10.7326\/0003-4819-113-11-8932240906"},{"key":"i8750-7315-109-3-235-b13","series-title":"Eur J Clin Invest","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/eci.12449","article-title":"Antiphospholipid syndrome: an update","volume":"45","author":"Merashli \n M,","year":"2015","unstructured":"Merashli \n M, \n \n \n Noureldine \n MHA, \n \n \n Uthman \n I, \n \n et al: \n Antiphospholipid syndrome: an update. Eur J Clin Invest45: 653, 2015.2585144810.1111\/eci.12449"},{"key":"i8750-7315-109-3-235-b14","series-title":"Arthritis Rheum","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1002\/art.24701","article-title":"Association of STAT4 and BLK, but not BANK1 or IRF5, with primary antiphospholipid syndrome","volume":"60","author":"Yin \n H,","year":"2009","unstructured":"Yin \n H, \n \n \n Orietta \n BM, \n \n \n Delgado-Vega \n AM, \n \n et al: \n Association of STAT4 and BLK, but not BANK1 or IRF5, with primary antiphospholipid syndrome. Arthritis Rheum60: 2468, 2009.10.1002\/art.24701"},{"key":"i8750-7315-109-3-235-b15","series-title":"Ann Rheum Dis","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicenter prospective study of 1000 patients","volume":"74","author":"Cervera \n R,","year":"2015","unstructured":"Cervera \n R, \n \n \n Serrano \n R, \n \n \n Pons-Estel \n G, \n \n et al: \n Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicenter prospective study of 1000 patients. Ann Rheum Dis74: 1011, 2015.10.1136\/annrheumdis-2013-20483824464962"},{"key":"i8750-7315-109-3-235-b16","series-title":"Arthritis Rheum","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1, 000 patients","volume":"46","author":"Cervera \n R,","year":"2002","unstructured":"Cervera \n R, \n \n \n Piette \n JC, \n \n \n Font \n J, \n \n et al: \n Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1, 000 patients. Arthritis Rheum46: 1019, 2002.10.1002\/art.10187"},{"key":"i8750-7315-109-3-235-b17","series-title":"Semin Thromb Hemost","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1055\/s-0034-1390003","article-title":"Thrombotic risk in the antiphospholipid syndrome","volume":"40","author":"Lim \n W:","year":"2014","unstructured":"Lim \n W: \n \n \n Thrombotic risk in the antiphospholipid syndrome. Semin Thromb Hemost40: 741, 2014.10.1055\/s-0034-139000325299926"},{"key":"i8750-7315-109-3-235-b18","series-title":"Auto Immun Highlights","first-page":"1","article-title":"Treatment of the antiphospholipid syndrome","volume":"5","author":"Galli \n M:","year":"2013","unstructured":"Galli \n M: \n \n \n Treatment of the antiphospholipid syndrome. Auto Immun Highlights5: 1, 2013.26000150"},{"key":"i8750-7315-109-3-235-b19","series-title":"Curr Opin Rheumatol","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/BOR.0000000000000269","article-title":"Treatment of catastrophic antiphospholipid syndrome","volume":"28","author":"Kazzaz \n NM,","year":"2016","unstructured":"Kazzaz \n NM, \n \n \n McCune \n WJ, \n \n \n Knight \n JS: \n \n \n Treatment of catastrophic antiphospholipid syndrome. Curr Opin Rheumatol28: 218, 2016.10.1097\/BOR.000000000000026926927441"},{"key":"i8750-7315-109-3-235-b20","series-title":"Arch Intern Med","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1001\/archinte.1992.00400230023004","article-title":"Blue toe syndrome causes and management","volume":"152","author":"O'Keeffe \n ST,","year":"1992","unstructured":"O'Keeffe \n ST, \n \n \n Woods \n BO, \n \n \n Breslin \n DJ, \n \n et al: \n Blue toe syndrome causes and management. Arch Intern Med152: 2197, 1992.10.1001\/archinte.1992.004002300230041444678"},{"key":"i8750-7315-109-3-235-b21","series-title":"J Am Acad Dermatol","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2008.09.038","article-title":"Blue (or purple) toe syndrome","volume":"60","author":"Hirschmann \n JV,","year":"2009","unstructured":"Hirschmann \n JV, \n \n \n Raugi \n GJ: \n \n \n Blue (or purple) toe syndrome. J Am Acad Dermatol60: 1, 2009.10.1016\/j.jaad.2008.09.03819103358"},{"key":"i8750-7315-109-3-235-b22","series-title":"J Vasc Surg","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/0741-5214(86)90111-4","article-title":"The blue toe syndrome: hemodynamics and therapeutic correlates of outcome","volume":"3","author":"Wingo \n JP,","year":"1986","unstructured":"Wingo \n JP, \n \n \n Nix \n ML, \n \n \n Greenfield \n LJ, \n \n et al: \n The blue toe syndrome: hemodynamics and therapeutic correlates of outcome. J Vasc Surg3: 475, 1986.10.1016\/0741-5214(86)90111-43512857"},{"key":"i8750-7315-109-3-235-b23","series-title":"Arch Surg","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1001\/archsurg.1976.01360290097015","article-title":"Blue toe syndrome: an indication for limb salvage surgery","volume":"111","author":"Karmody \n AM,","year":"1976","unstructured":"Karmody \n AM, \n \n \n Powers \n SR, \n \n \n Monaco \n VJ, \n \n et al: \n Blue toe syndrome: an indication for limb salvage surgery. Arch Surg111: 1263, 1976.98507510.1001\/archsurg.1976.01360290097015"},{"key":"i8750-7315-109-3-235-b24","series-title":"Emerg Med Clin North Am","first-page":"637","article-title":"Blue toe syndrome, ischemic pain treated with digital block","volume":"10","author":"Belsky \n J,","year":"2015","unstructured":"Belsky \n J, \n \n \n Alvey \n H, \n \n \n Bencze \n ATB, \n \n et al: \n Blue toe syndrome, ischemic pain treated with digital block. Emerg Med Clin North Am10: 637, 2015."},{"key":"i8750-7315-109-3-235-b25","series-title":"Mayo Clin Proc","doi-asserted-by":"publisher","first-page":"292","DOI":"10.4065\/70.3.292","article-title":"Spittell PC: 79-year-old woman with blue toes","volume":"70","author":"Abdelmalek \n MF,","year":"1995","unstructured":"Abdelmalek \n MF, \n \n \n Spittell PC: 79-year-old woman with blue toes. Mayo Clin Proc70: 292, 1995.10.4065\/70.3.2927861818"},{"key":"i8750-7315-109-3-235-b26","series-title":"J Cardiovasc Surg","first-page":"975","article-title":"Blue toe syndrome","volume":"8","author":"Sharifkazemi \n MB,","year":"2007","unstructured":"Sharifkazemi \n MB, \n \n \n Zamirian \n M, \n \n \n Aslani \n A: \n \n \n Blue toe syndrome. J Cardiovasc Surg8: 975, 2007."},{"key":"i8750-7315-109-3-235-b27","series-title":"Am J Surg","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/0002-9610(84)90181-8","article-title":"Blue digit syndrome: urgent indication for digital salvage","volume":"147","author":"Lee \n BY,","year":"1984","unstructured":"Lee \n BY, \n \n \n Brancato \n RF, \n \n \n Thoden \n WR, \n \n et al: \n Blue digit syndrome: urgent indication for digital salvage. Am J Surg147: 418, 1984.10.1016\/0002-9610(84)90181-86703217"},{"key":"i8750-7315-109-3-235-b28","series-title":"Ann Dermatol","doi-asserted-by":"publisher","first-page":"400","DOI":"10.5021\/ad.2016.28.3.400","article-title":"Blue toe syndrome as an early sign of disseminated intravascular coagulation","volume":"28","author":"Choi \n KH,","year":"2016","unstructured":"Choi \n KH, \n \n \n Yoo \n J, \n \n \n Huh \n JW, \n \n et al: \n Blue toe syndrome as an early sign of disseminated intravascular coagulation. Ann Dermatol28: 400, 2016.10.5021\/ad.2016.28.3.40027274647"},{"key":"i8750-7315-109-3-235-b29","series-title":"Int J Lab Hematol","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/ijlh.12507","article-title":"Labratory testing for antiphospholipid syndrome","volume":"38","author":"Pengo \n V,","year":"2016","unstructured":"Pengo \n V, \n \n \n Banzato \n A, \n \n \n Bison \n E, \n \n et al: \n Labratory testing for antiphospholipid syndrome. Int J Lab Hematol38: 1, 2016.10.1111\/ijlh.12507"},{"key":"i8750-7315-109-3-235-b30","series-title":"Lupus","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1177\/0961203316636467","article-title":"Musculoskeletal manifestations of the antiphospholipid syndrome","volume":"25","author":"Noureldine \n M,","year":"2016","unstructured":"Noureldine \n M, \n \n \n Khamashta \n M, \n \n \n Merashli \n M, \n \n et al: \n Musculoskeletal manifestations of the antiphospholipid syndrome. Lupus25: 451, 2016.10.1177\/096120331663646726923284"},{"key":"i8750-7315-109-3-235-b31","series-title":"Hematology","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1182\/asheducation-2013.1.675","article-title":"Antiphospholipid syndrome","volume":"15","author":"Lim \n W:","year":"2013","unstructured":"Lim \n W: \n \n \n Antiphospholipid syndrome. Hematology15: 675, 2013.10.1182\/asheducation-2013.1.675"},{"key":"i8750-7315-109-3-235-b32","series-title":"Curr Rheumatol Rep","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11926-016-0566-z","article-title":"Emerging therapies in antiphospholipid syndrome","volume":"18","author":"Andrade \n D,","year":"2016","unstructured":"Andrade \n D, \n \n \n Tektonidou \n M: \n \n \n Emerging therapies in antiphospholipid syndrome. Curr Rheumatol Rep18: 22, 2016.10.1007\/s11926-016-0566-z26995745"},{"key":"i8750-7315-109-3-235-b33","series-title":"Lupus","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1177\/0961203314540354","article-title":"Domain I: the hidden face of antiphospholipid syndrome","volume":"23","author":"Pericleous \n C,","year":"2014","unstructured":"Pericleous \n C, \n \n \n Rahman \n A: \n \n \n Domain I: the hidden face of antiphospholipid syndrome. Lupus23: 1320, 2014.10.1177\/0961203314540354"},{"key":"i8750-7315-109-3-235-b34","series-title":"Am J Med","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.amjmed.2012.11.001","article-title":"Odd spot for a clot: primary antiphospholipid syndrome","volume":"126","author":"Schattner \n A,","year":"2013","unstructured":"Schattner \n A, \n \n \n Teshler \n M, \n \n \n Kozac \n N: \n \n \n Odd spot for a clot: primary antiphospholipid syndrome. Am J Med126: 217, 2013.10.1016\/j.amjmed.2012.11.00123410561"}],"container-title":["Journal of the American Podiatric Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/japmaonline.org\/view\/journals\/apms\/109\/3\/17-108.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/japma\/article-pdf\/109\/3\/235\/2457949\/17-108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/japmaonline.org\/downloadpdf\/journals\/apms\/109\/3\/17-108.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/japmaonline.org\/downloadpdf\/journals\/apms\/109\/3\/17-108.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T10:17:41Z","timestamp":1783505861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1930-8264\/109\/3\/235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":34,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.7547\/17-108","relation":{},"ISSN":["8750-7315","1930-8264"],"issn-type":[{"value":"8750-7315","type":"print"},{"value":"1930-8264","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}